EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) saw an upside of 2.70% to close Monday at $1.90 after adding $0.05 on the day. The 5-day average trading volume is 1,442,320 shares of the company’s common stock. It has gained $1.9773 in the past week. An average of 3,014,035 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,185,438.
EYEG’s 1-month performance is 16.56% or $0.2700 on its low of $1.5801 reached on 09/13/21. The company’s shares have touched a 52-week low of $1.44 and high of $8.18, with the stock’s rally to the 52-week high happening on 02/17/21. YTD, EYEG has lost -61.46% or -$3.0300. However, the current price is down -76.77%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Aug 02, 71 days have gone by since the last insider trading activity for EyeGate Pharmaceuticals Inc. (EYEG). ARMISTICE CAPITAL, LLC (10% Owner) most recently sold 192,775 shares at $2.40 per share on Aug 02. This transaction cost the insider $463,046. 10% Owner, ARMISTICE CAPITAL, LLC, sold 68,188 shares at a price of $2.69 on Jul 30. Then, on Jul 29, Director ARMISTICE CAPITAL, LLC sold 400,000 shares at a price of $3.00 per share. This transaction amounted to $1,200,000.
EyeGate Pharmaceuticals Inc. (EYEG) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.24 for the sector.EYEG stock has a beta of 0.88. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 2001.00 while the price-to-book (PB) in the most recent quarter is 1.28.
EyeGate Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 3.10, with the current ratio over the same period at 3.10 meaning that EYEG stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00The trailing 12-month EBITDA margin is -66444.48%. The firm’s gross profit as reported stood at $8.22 million against revenue of $12000.0.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected EYEG to announce -$0.42 per share in earnings in its latest quarter, but it posted -$0.35, representing a 16.70% surprise. EBITDA for the quarter stood at more than -$2.73 million. EYEG stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 7.65 million, with total debt at $0.31 million. Shareholders hold equity totaling $12.62 million
Let’s look briefly at EyeGate Pharmaceuticals Inc. (EYEG) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 51.26% to suggest the stock is trending Neutral, with historical volatility in this time period at 139.38%.
The stock’s 5-day moving average is $1.8420, reflecting a +4.40% or $0.0800 change from its current price. EYEG is currently trading +13.10% above its 20-day SMA, -54.65% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -24.60% and -67.80% respectively.
Stochastic %K and %D was 22.95% and 18.21% and the average true range (ATR) pointed at 0.1857. The RSI (14) points at 49.87%, while the 14-day stochastic is at 27.87% with the period’s ATR at 0.1943. The stock’s 9-day MACD Oscillator is pointing at -0.0333 and -0.0450 on the 14-day charts.
In the most recent analyst report for EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG), H.C. Wainwright reiterated its a Buy rating for the company but lifted their price target by $10 to $14. Analysts offering their rating for EYEG stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate EYEG as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is EYEG’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $9.50 and a high of $15.00, with their median price target at $11.00. Looking at these predictions, the average price target given by analysts is for EyeGate Pharmaceuticals Inc. (EYEG) stock is $11.83.